DRG Epidemiology's coverage of immune thrombocytopenic purpura (ITP)comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of ITP for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States and Europe.
DRG Epidemiology's ITP forecast will answer the following questions:
- Of all people diagnosed with immune thrombocytopenic purpura, how many in each country across the major mature pharmaceutical markets are drug treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of immune thrombocytopenic purpura over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of diagnosed cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following immune thrombocytopenic purpura subpopulations:
- Diagnosed prevalent cases by drug-treatment status.
Note: Coverage may vary by country.
- Immune Thrombocytopenic Purpura - Epidemiology - Mature Markets Data
- Key Findings
- Key Updates
- Diagnosed Prevalence of Chronic Immune Thrombocytopenic Purpura per 100,000 Among People of All Ages in 2018 and 2038
- Relative Sizes of Contributing Factors to the Trend in Diagnosed Prevalent Cases of Chronic Immune Thrombocytopenic Purpura Over the Next Twenty Years
- Analysis of the Prevalent Cases of Chronic Immune Thrombocytopenic Purpura in 2018 by Drug-Treated Status
- Epidemiology Data
- Diagnosed Incident Cases of Acute Immune Thrombocytopenic Purpura
- Diagnosed Prevalent Cases of Chronic Immune Thrombocytopenic Purpura
- Drug-Treated Prevalent Cases of Chronic Immune Thrombocytopenic Purpura
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Immune Thrombocytopenic Purpura
- Studies Excluded from the Analysis of Immune Thrombocytopenic Purpura
- Risk/Protective Factors
- Risk/Protective Factors for Immune Thrombocytopenic Purpura
- Literature Review
Author(s): Shilpa Thakur; Abey John, MPH
Shilpa Thakur is a medical graduate with a M.P.H from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics. She specializes in developing epidemiological forecasts for the multiple indications within the DRG syndicated portfolio.
Prior to joining Decision Resources, she monitored HIV sentinel surveillance 2016-2017 in Himachal Pradesh. She also has worked on to see the patterns of Antimicrobial resistance in India.
Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.
Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.